Skip to main content
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC — Investor Relations & Filings

Ticker · AYTU ISIN · US0547548745 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2024-06-18 Major Shareholding Noti…
Country US United States of America
Listing US AYTU

About AYTU BIOPHARMA, INC

https://aytubio.com/

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics. The company concentrates on advancing innovative medicines for complex central nervous system (CNS) diseases, with a particular emphasis on treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). Its business model involves identifying, acquiring, and commercializing new products to improve the quality of life for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2024-06-18 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 12, 2024, by Aytu BioPharma, Inc. It reports the entry into a material definitive agreement related to a loan and security agreement amendment, including details about new term loans and revolving credit facilities. The document includes descriptions of financing arrangements and amendments to loan agreements, which are typical content for a capital or financing update. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a press release or a report publication announcement but a regulatory filing disclosing material financing events. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7405 characters) supports it being a substantive filing rather than a brief announcement.
2024-06-18 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 15, 2024, by Aytu BioPharma, Inc. It announces the issuance of a press release regarding operational and financial results for the fiscal quarter ended March 31, 2024. The document states that a conference call and webcast are scheduled to discuss these results. The press release is attached as Exhibit 99.1. The document itself does not contain detailed financial statements or substantive financial data but rather announces the results and the upcoming call. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. The document length is 4188 characters, which is typical for an 8-K earnings release announcement. Therefore, the appropriate classification is ER with high confidence.
2024-05-15 English
FORM 10-Q
Interim / Quarterly Report Q3 2024
2024-05-15 English
Annual Report 2024
Annual Report
2024-05-10 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The text explicitly states it is a 'Definitive Additional Materials' filing related to a proxy statement. Proxy statements and related materials are classified under 'Proxy Solicitation & Information Statement' (PSI). The document length is short and it is not the full proxy statement but additional materials, which still fall under the PSI category. Therefore, the correct classification is PSI with high confidence.
2024-05-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.